Amphetamine Resin Particles for Once-Daily ADHD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ADHD treatments, such as ADDERALL XR and METADATE CD, face challenges including difficulty in administration for children, especially in school settings, due to the need for multiple doses throughout the day, which can lead to compliance issues and decreased efficacy, and many individuals struggle with swallowing solid dosage forms.
Innovation Solution
The development of pharmaceutical compositions comprising a mixture of dextro- and levo-amphetamine in drug-resin particles with both immediate and delayed release coatings, providing a liquid or chewable form that allows for a once-daily administration, enhancing taste masking and reducing the risk of dose dumping, and simplifying the supply chain by using fewer amphetamine salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple doses are administered throughout the day to maintain therapeutic effect, then the therapeutic efficacy is improved, but the compliance difficulty and administrative complexity increase
Solution Approach 1:
The patent divides the total daily dose into multiple distinct dosage forms with different release characteristics (immediate-release capsules and extended-release capsules), allowing the therapeutic effect to be maintained throughout the day while reducing the number of administration events. The segmentation of release profiles enables sustained therapeutic levels without requiring multiple separate dosing events.
Solution Approach 2:
The extended-release capsule is designed to release the medication gradually over several hours, performing the action of maintaining therapeutic levels in advance before the next scheduled dose is needed. This preliminary action ensures continuous therapeutic effect without requiring frequent re-dosing, thereby improving compliance.
2Duration of action of moving object
If solid dosage forms are used for ADHD treatment, then the drug can be administered once daily with extended release, but the ease of ingestion deteriorates for children and individuals with dysphagia
Solution Approach 1:
The patent utilizes the fluid properties of liquid suspension formulations to improve ease of ingestion. The liquid form can be easily swallowed by children and individuals with dysphagia, eliminating the swallowing difficulties associated with solid dosage forms while maintaining the extended-release characteristics through the use of delayed-release capsules in the suspension.
3Speed
If immediate-release amphetamine salts are used, then the drug releases quickly for rapid effect, but the duration of action is too short requiring multiple doses
Solution Approach 1:
The patent segments the amphetamine salts into two distinct release profiles: immediate-release capsules for rapid initial effect and extended-release capsules for sustained therapeutic levels. This segmentation allows both quick onset and prolonged duration to be achieved within the same dosing regimen, eliminating the need for multiple doses while maintaining rapid initial effectiveness.
Solution Approach 2:
The patent creates a composite dosage regimen combining immediate-release and extended-release formulations. This composite approach integrates the advantages of both release types—rapid onset from immediate-release and prolonged duration from extended-release—into a single coordinated treatment protocol that maintains therapeutic efficacy throughout the day without requiring multiple administration events.
4Duration of action of moving object
If four amphetamine salts are used in ADDERALL XR formulation, then the extended release profile is achieved, but the device complexity and manufacturing complexity increase
Solution Approach 1:
The patent extracts the essential functional requirement (extended-release profile) from the complex four-salt formulation and achieves it through a simplified two-component system: immediate-release capsules and extended-release capsules. By taking out only the necessary release characteristics and implementing them through simpler formulations, the patent reduces manufacturing complexity while maintaining the desired extended-release therapeutic profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions offer an effective, prolonged treatment with improved bioavailability and reduced exposure to toxic compounds, providing a bioequivalent plasma profile to existing treatments while being easier to ingest and administer, particularly suitable for children and individuals with dysphagia.
Implementation Method 1
adsorbing amphetamines onto a sulphonic acid cation exchange resin from which the drug is slowly and uniformly released by gastric and intestinal juices
Implementation Method 2
adsorbing amphetamines onto a sulphonic acid cation exchange resin
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.